In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...
The US Food and Drug Administration (FDA) has approved Sarclisa (isatuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first line treatment option for adult patients ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
XPOVIO® is the first and only approved XPO1 inhibitor in Thailand. XPOVIO® has been approved for multiple indications in nine markets across the APAC region. Antengene has submitted a new drug applica ...
Mayo Clinic on MSN34m
COVID-19 drugs: Are there any that work?The first, called nirmatrelvir, blocks the activity of an enzyme the COVID-19 virus needs to copy itself, also called repl ...
Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option ...
Zevra Therapeutics' drug, Miplyffa, for treating a rare and fatal genetic disorder will have a wholesale acquisition cost ranging between $40,000 and $106,000 per month depending on dosage, the ...
The spray could be an alternative for people who are averse to getting injections, or otherwise find it difficult or ...
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve ...
The Gadgets 360 Best Tablets page shows the top-rated tablets reviewed by us in the recent past. The tablets were launched less than 2 years ago, and have received a rating of 8 or above. When you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback